NeuroSense Granted Patents In Europe, Japan, And Israel For Its ALS Drug PrimeC
Portfolio Pulse from Benzinga Newsdesk
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has been granted patents in Europe, Japan, and Israel for its ALS drug PrimeC. The patents relate to NeuroSense's unique fixed-dose combination of ciprofloxacin and celecoxib, the active ingredients in PrimeC. Corresponding patents have been issued in the U.S., Canada, and Australia and are valid through 2038. Clinical topline results from Phase 2b ALS trial are expected in H2 2023.
September 19, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NeuroSense Therapeutics has been granted patents for its ALS drug PrimeC in multiple countries, which could strengthen its market position and potentially boost its stock price.
The granting of patents for NeuroSense's ALS drug PrimeC in multiple countries is a significant development for the company. This could strengthen its market position by providing it with exclusive rights to sell the drug in these markets, potentially leading to increased revenues and a boost in its stock price. Furthermore, the anticipation of the Phase 2b ALS trial results in H2 2023 could also create positive sentiment among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100